The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|September 15, 2005
Biogen to Cut Jobs
Author(s)Pharmaceutical Technology Editors
Biogen to Cut Jobs
Advertisement
The downsizing will be part of a restructuring plan conceived afterreviews of business processes, geographic locations, and staffing. Cutswill be made at the managerial and staff level, and are expected toequateto approximately 650 jobs, mostly in the San Diego, California, area,and at thecompany's manufacturing operations at Research Triangle Park, NorthCarolina.
In addition, the company plans to sell its NICO clinical manufacturingplant in San Diego and property in Oceanside, California. Also on thechopping block is the psoriasis drug, "Amevive," which had revenue of$43million in 2004. Biogen expects the plan to take effect by the end ofthe year.
Biogen Idec said that it is considering using the additional funds fornew product opportunities and 'the acquisition of products andcompanies, as well as expanding collaborative research with academicinstitutions and teaching hospitals."
In related news, Biogen also announced that Michael Gilman, executivevice-president of research, is leaving the company, effective Nov. 8.Alphonse Galdes, vice-president of drug discovery, and Rainer Fuchs,vice-president of research informatics and operations, will take hisplace in the interim.
–George Koroneos
Advertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement